ImmuPharma plc IMM
LSE · United Kingdom · Health Technology
GBp 3.50+0.25 (+7.54%)
Market closed· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
ImmuPharma PLC (AIM:IMM, FRA:25I) has signed up Kymos Group as its bioanalytical partner for diabetes drug Kapiglucagon. That completes the outsourced team needed to file for human trials in the US. ValiRx PLC (AIM:VAL, FRA:EAJF) is set to get a second European patent for its cancer-killing peptide from subsidiary Cytolytix. It's targeting triple negative breast cancer and is in talks with a major pharma company. Tertiary Minerals PLC (AIM:TYM, OTC:TTIRF, FRA:TMU) has drilled some strong copper and silver hits at its Mushima North project in Zambia. Lab results are due in the coming weeks, wit
Thermo Fisher Scientific (NYSE:TMO) has been selected by ImmuPharma as the key drug product and contract development manufacturer for its Kapiglucagon diabetes treatment program. The partnership covers development and manufacturing support for Kapiglucagon, an experimental therapy aimed at addressing diabetes. This agreement adds a new project to Thermo Fisher Scientific’s pharmaceutical services portfolio, focused on complex drug development work. For investors tracking Thermo Fisher...
Seeing Machines (AIM:SEE) has won a new driver monitoring contract with a European carmaker worth around $5 million in lifetime revenue, just as new EU safety rules make the technology mandatory on new vehicles. Production starts in 2028, with the system built into a rear-view mirror for easy deployment across multiple platforms. Frontier IP (LSE:FIPP) says portfolio company Cambridge Raman Imaging has secured a €400,000 European grant to scale up its AI-powered pharmaceutical quality control technology. The company has also appointed a China-based distributor with over 100 customers globally.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.